SPCX Research Note — Evidence Meets Supply
SpaceX operating progress meets SPCX’s unresolved post-IPO tape as first earnings and a large August share release test public-market demand.
CAMS Free Update
Market Structure: Rates Divide Market Leadership — August 4, 2026
SPY is holding its intermediate trend, but a 4.74% 10-year yield, technology weakness, and 38% watchlist breadth keep the regime mixed.
WST Research Note — Good Quarter, Harder Proof
West Pharmaceutical’s strong quarter meets a harder test from valuation, market structure and unresolved oral-drug substitution risk.
MOH Research Note — Medical Costs Stay Unresolved
Molina's raised outlook faces a 92.2% medical-cost ratio, a 57% ACA membership decline and weak price structure.
ASML Research Note — Cycle Still Needs Bookings Proof
ASML’s Q2 revenue rose 11% and new-system shipments rose 28%, but missing net bookings and weak price structure leave the cycle unconfirmed.
MS Research Note — Results Lead the Tape
Morgan Stanley’s record quarter strengthens the operating case, while sector lag and an unresolved Wealth Management question raise the proof bar.
UNH Research Note — Repair Needs More Proof
UnitedHealth improved Medicare cost evidence in July, but commercial pressure and a broader federal inquiry keep the repair incomplete.
Market Structure: Leadership Converges Before Earnings — August 3, 2026
Healthcare, financials, and energy lead by similar margins, but this week’s company reports will test three very different market trends.
QQQ Research Note — Long Trend, Narrow Leadership
QQQ held its long-term trend, but narrow breadth, technology weakness and rising yields leave the August evidence window unusually important.
JPM Research Note — Record Quarter, Higher Bar
JPMorgan’s record quarter supports the operating case, but rates, credit and a premium valuation leave the next evidence unusually important.